According to filings with the U.S. Securities and Exchange Commission, ForCast Orthopedics is raising up to $10,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About ForCast Orthopedics
ForCast Orthopedics, Inc is an early stage combination device company with an important mission for improving treatment of orthopedic infection, specifically periprosthetic joint and spinal infections. Treatment options today are poor and frequently fail with persistent infection requiring multiple surgeries. We’ve heard many stories told about patients suffering after pursuing a common, reliable arthroplasty procedure to improve their quality of life. With any surgery, infection is a known risk and troublesome. Too frequently, treatment for periprosthetic infections becomes tragic. ForCast Orthopedics was founded by a leading orthopedic surgeon and an experienced med-tech executive. Together with an experienced team, we are pursuing an improved approach for PJI treatment. Local antibiotic delivery allows us to use available and potent antibiotics against biofilms formed on artificial material surfaces that are the root cause of current treatment failure. However, current antibiotic administration methods (PICC lines, cement spacers and beads) cannot achieve biofilm eradication concentrations overtime at the infection site, e.g. sub-therapeutic for biofilm! Intraarticular Antibiotic Injection (IAI) therapy has been demonstrated in TKA and THA infections to be safe and effective through previously published clinical research using a manual method. Our products will automate this approach to duplicate successful patient outcomes, reduce cost, patient morbidity and expanding clinical adoption. .

To learn more about ForCast Orthopedics, visit https://forcastortho.com/
ForCast Orthopedics Linkedin Page: https://www.linkedin.com/company/forcast-ortho/

Contact:
Peter Noymer, Chief Executive Officer
408-656-5510
https://www.linkedin.com/in/peter-noymer-3832b26/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.